Hanall Biopharma Company Overview

  • Founded
  • 1973

Founded
  • Status
  • Public

  • Employees
  • 315

Employees
  • Stock Symbol
  • 009420

Stock Symbol
  • Investments
  • 6

  • Share Price
  • $10.88

  • (As of Friday Closing)

Hanall Biopharma Company General Information

Description

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Delivery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
  • 6th Fl., I-Space Building, 11-10
  • Sincheon-Dong
  • Songpa-Gu, 138-922
  • South Korea
+49 08222 0000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hanall Biopharma Company Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.88 $10.84 $8.72 - $18.25 $551M 50.7M 148K

Hanall Biopharma Company Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 425,344 839,194 1,676,628 1,521,868
Revenue 83,960 88,696 75,042 93,006
EBITDA 2,693 9,370 16,931 15,473
Net Income (301) 7,767 16,740 16,444
Total Assets 130,234 166,785 201,786 165,221
Total Debt 761 1,122 506 491
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hanall Biopharma Company Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hanall Biopharma Company‘s full profile, request access.

Request a free trial

Hanall Biopharma Company Patents

Hanall Biopharma Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10336825-B2 Antibody binding to fcrn for treating autoimmune diseases Active 30-Apr-2014 0000000000
US-20170210805-A1 Antibody binding to fcrn for treating autoimmune diseases Active 30-Apr-2014 0000000000
EP-3137504-A4 Antibody binding to fcrn for treating autoimmune diseases Pending 30-Apr-2014 0000000000
EP-3137504-A1 Antibody binding to fcrn for treating autoimmune diseases Pending 30-Apr-2014 0000000000
US-20190135917-A1 Antibody binding to fcrn for treating autoimmune diseases Inactive 30-Apr-2014 C07K16/283
To view Hanall Biopharma Company’s complete patent history, request access »

Hanall Biopharma Company Executive Team (4)

Name Title Board Seat Contact Info
Jeong Seung-won Chief Executive Officer
Sung-yon Lim Board Member & Managing Director
SeungKook Park Ph.D Executive Vice President & Head, Research
You’re viewing 3 of 4 executive team members. Get the full list »

Hanall Biopharma Company Board Members (2)

Name Representing Role Since
00000000 000 Hanall Biopharma Company Founder & Chairman 000 0000
0000-000 000 Hanall Biopharma Company Board Member & Managing Director 000 0000
To view Hanall Biopharma Company’s complete board members history, request access »

Hanall Biopharma Company Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hanall Biopharma Company Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hanall Biopharma Company‘s full profile, request access.

Request a free trial

Hanall Biopharma Company Investments (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 11-Apr-2022 00000 0000 Drug Discovery
00000000 0000 20-Aug-2021 00000 0000 000 Drug Discovery
000000 000000 30-Jul-2021 00000 0000 000 Drug Discovery
0000000000 19-Jul-2019 00000 0000 000.00 Drug Discovery
ImmunoMet 05-Feb-2016 Early Stage VC 00.00 Drug Discovery 0000-000
You’re viewing 5 of 6 investments. Get the full list »

Hanall Biopharma Company Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000000 19-Jul-2019 00000 00000 00 000.00 Completed
  • 4 buyers
To view Hanall Biopharma Company’s complete exits history, request access »